2. Clinical Teratology

2.1. Introduction

2.2. Evaluating the Patient and Her Exposure

2.3. Recognized Teratogenic Exposures

2.4. Paternal Exposures and Maternal Exposures Before or Shortly After Conception

2.5. Future Perspective

2.6. Conclusion


3.1. Intellectual Disability and Global Developmental Delay

3.2. Global Developmental Delay

3.3. Definition of a Diagnosis

3.4. Whole Exome Sequencing

3.5. Whole Genome Sequencing

3.6. Phenotyping

3.7. Genetic Mechanisms of ID

3.8. Diagnostic Testing of Patients With ID of Unknown Cause

3.9. Cytogenomic Copy Number Abnormalities

3.10. X-Linked ID
3.11. Fragile X Syndrome
3.12. Autism Spectrum Disorders
3.13. Inborn Errors of Metabolism and ID
3.14. CNS Malformations, Intellectual Disability and Brain Imaging
3.15. Summary

4. Abnormal Body Size and Proportion
   Glossary
   4.1. Introduction
   4.2. Approach to the Patient With Abnormal Stature
   4.3. Mechanisms of Growth
   4.4. Pathologic Short Stature
   4.5. Pathologic Overgrowth
   4.6. Conclusion

Chapter 5. Cytogenetic Analysis
   5.1. Introduction
   5.2. Milestones in Human Cytogenetics
   5.3. Indications for Cytogenetic Analysis
   5.4. Tissue Samples and Cell Culture
   5.5. Chromosome Banding
5.6. Normal Human Karyotype

5.7. Chromosome Abnormalities

5.8. In Situ Hybridization

6. Diagnostic Molecular Genetics

6.1. Introduction

6.2. Indications for Molecular Genetic Testing

6.3. Technical Approaches to Molecular Genetic Testing

6.4. Molecular Genetic Diagnosis of Some Commonly Tested Diseases

6.5. Mitochondrial DNA Disorders

6.6. Other Targets of Molecular Genetic Screening

6.7. Pharmacogenetic Testing

6.8. Quality Assurance, Reimbursement, and Regulatory Issues

6.9. Internet Resources for Molecular Genetic Testing

6.10. Societal Impact of the New Genetic Technology

6.11. Future Directions

7. Therapies for Lysosomal Storage Diseases

7.1. Introduction

7.2. Enzyme Replacement Therapy
7.3. Bone Marrow Transplantation
7.4. Substrate Reduction Therapy
7.5. Pharmacologic Chaperone Therapy
7.6. Emerging Therapies: Gene Therapy and Genome Editing

8. Transplantation Genetics
8.1. The Major Histocompatibility Complex
8.2. Historical Iter Toward Histocompatibility Definition
8.3. Currently Most Used Methods for HLA Typing
8.4. Clinical Significance of HLA Molecular Typing
8.5. Stem Cells and Transplantation
8.6. Concluding Remarks

9. Genetic Evaluation for Common, Chronic Disorders of Adulthood
9.1. Background
9.2. Outcomes of Genetic Services
9.3. The Process of Genetic Consultation for Common, Chronic Diseases of Adulthood
9.4. Genetic Healthcare Models

Summary

10. Carrier Screening and Heterozygote Testing
Glossary

10.1. Introduction

10.2. Carrier Screening in Clinical Practice

10.3. Carrier Screening in Individuals of Defined Subpopulation Groups

10.4. Therapeutic Implications for Heterozygotes

10.5. Sensitivity and Specificity

10.6. Cost and Feasibility

10.7. Genetic Counseling and Informed Consent

10.8. Conclusions

11. Circadian Rhythms and Disease

11.1. Introduction

11.2. Molecular Mechanisms

11.3. Central and Peripheral Clocks

11.4. Circadian Diseases

11.5. Metabolic and Cardiovascular Disorders

11.6. Cancer

11.7. Psychologic and Neurologic Diseases and Circadian Rhythms

11.8. Chronotherapy
11.9. Concluding Remarks

12. The Genomic Health Record: Current Status and Vision for the Future

12.1. Introduction

12.2. Conclusion

13. Ethical and Social Issues in Clinical Genetics

13.1. Introduction

13.2. The Historical Context

13.3. Genetic Counseling, Testing, and Screening

13.4. Diagnostic Genetic Testing

13.5. Predictive Genetic Testing

13.6. Confidentiality

13.7. Genetic Testing in Childhood

13.8. Population Genetic Screening

13.9. Other Challenges in Genetic Counseling

14. Genetics and Genomics in Public Health


14.2. The Purposes of Public Health

14.3. The Public Health System Infrastructure
14.4. Evolution and Convergence of Two Fields of Science—Public Health and Genetics/Genomics

14.5. Future Direction for Public Health Genetics/Genomics

15. Implementation of Genomic Medicine: An International Perspective

15.1. Introduction

15.2. Large-Scale Genomic Medicine Initiatives

15.3. National Genomic Medicine Initiatives

15.4. Large-Scale Regional Genome Initiatives

15.5. Corporate Genomic Medicine Initiatives

15.6. Studying Founder Populations

15.7. Conclusions and Future Perspectives

15.8. Competing Interests

Index
Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library

ISBN: 978-0-12-812536-6

For information on all Academic Press publications visit our website at https://www.elsevier.com/books-and-journals

Publisher: Andre Wolff
Senior Acquisition Editor: Peter B. Linsley
Editorial Project Manager: Pat Gonzalez
Production Project Manager: Punithavathy Govindaradjane
Designer: Matthew Limbert

Typeset by TNQ Technologies
List of Contributors

Sura Alwan,  Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

Angus John Clarke
Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, Wales, United Kingdom
Institute of Medical Genetics, School of Medicine, Heath Park, Cardiff, Wales, United Kingdom

Kenneth H. Astrin
Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
Department of Preclinical Sciences, New York College of Podiatric Medicine, New York, NY, United States

Marina Bartsakoulia,  University of Patras School of Health Sciences, Department of Pharmacy, Patras, Greece

Deepika D’Cunha Burkardt,  Medical Genetics Resident, Center for Human Genetics, University Hospitals/Case Western Reserve University, Cleveland, OH, United States

Constantina Chalikiopoulou,  University of Patras School of Health Sciences, Department of Pharmacy, Patras, Greece

Joshua L. Deignan,  Departments of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, United States

Robert J. Desnick,  Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
Shweta U. Dhar, Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, United States

Debra Lochner Doyle, Washington State Department of Health Screening and Genetics, Kent, WA, United States

Malcolm A. Ferguson-Smith, Cambridge Resource Centre for Comparative Genomics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom

Jan M. Friedman, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

John M. Graham Jr.
Consultant in Clinical Genetics and Dysmorphology, Cedars-Sinai Medical Center, Los Angeles, CA, United States
Consultant in Clinical Genetics and Dysmorphology, Harbor-UCLA Medical Center, Torrance, CA, United States
Professor Emeritus of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

Daniel Graziano, Tissue Typing Laboratory, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, PA, United States

Wayne W. Grody, UCLA School of Medicine, Los Angeles, CA, United States

Rachel Irving, Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, Wales, United Kingdom

Kenneth L. Jones
Department of Pediatrics, University of California, San Diego, CA, United States
Rady Children’s Hospital, San Diego, CA, United States

Marilyn C. Jones
Department of Pediatrics, University of California, San Diego, CA, United States
Rady Children’s Hospital, San Diego, CA, United States

Theodora Katsila, University of Patras School of Health Sciences,
the University of Pennsylvania, Philadelphia, PA, United States

Efthymios Skoufas, University of Patras School of Health Sciences, Department of Pharmacy, Patras, Greece

Nancy B. Spinner
The Children’s Hospital of Philadelphia, Pennsylvania, PA, United States
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Pennsylvania, PA, United States

Massimo Trucco, Institute of Cellular Therapeutics, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, PA, United States

Evangelia-Eirini Tsermpini, University of Patras School of Health Sciences, Department of Pharmacy, Patras, Greece

Marc S. Williams, Genomic Medicine Institute, Geisinger, Danville, PA, United States

Shirley L. Zhang
Chronobiology Program at Penn, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States
Howard Hughes Medical Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States
Preface to the Seventh Edition of Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics

The first edition of Emery and Rimoin’s Principles and Practice of Medical Genetics appeared in 1983. This was several years prior to the start of the Human Genome Project in the early days of molecular genetic testing, a time when linkage analysis was often performed for diagnostic purposes. Medical genetics was not yet a recognized medical specialty in the United States, or anywhere else in the world. Therapy was mostly limited to a number of biochemical genetic conditions, and the underlying pathophysiology of most genetic disorders was unknown. The first edition was nevertheless published in two volumes, reflecting the fact that genetics was relevant to all areas of medical practice.

Thirty-five years later we are publishing the seventh edition of Principles and Practice of Medical Genetics and Genomics. Adding “genomics” to the title recognizes the pivotal role of genomic approaches in medicine, with the human genome sequence now in hand and exome/genome-level diagnostic sequencing becoming increasingly commonplace. Thousands of genetic disorders have been matched with the underlying genes, often illuminating pathophysiological mechanisms and in some cases enabling targeted therapies. Genetic testing is becoming increasingly incorporated into specialty medical care, though applications of adequate family
history, genetic risk assessment, and pharmacogenetic testing are only gradually being integrated into routine medical practice. Sadly, this is the first edition of the book to be produced without the guidance of one of the founding coeditors, Dr David Rimoin, who passed away just as the previous edition went to press.

The seventh edition incorporates two major changes from previous editions. The first is publication of the text in 11 separate volumes. Over the years the book had grown from two to three massive volumes, until the electronic version was introduced in the previous edition. The decision to split the book into multiple smaller volumes represents an attempt to divide the content into smaller, more accessible units. Most of these are organized around a unifying theme, for the most part based on specific body systems. This may make the book more useful to specialists who are interested in the application of medical genetics to their area but do not wish to invest in a larger volume that covers all areas of medicine. It also reflects our recognition that genetic concepts and determinants now underpin all medical specialties and subspecialties. The second change might seem on the surface to be a regressive one in today’s high-tech world—the publication of the 11 volumes in print rather than strictly electronic form. However, feedback from our readers, as well as the experience of the editors, indicated that access to the web version via a password-protected site was cumbersome, and printing a smaller volume with two-page summaries was not useful. We have therefore returned to a full print version, although an eBook is available for those who prefer an electronic version.

One might ask whether there is a need for a comprehensive text in an era of instantaneous internet searches for virtually any information, including authoritative open sources such as Online Mendelian Inheritance in Man and GeneReviews. We recognize the value of these and other online resources, but believe that there is still a place for the long-form prose approach of a textbook. Here the authors have the opportunity to tell the story of their area of medical genetics and genomics, including in-depth background about pathophysiology, as well as giving practical advice for medical practice. The willingness of
our authors to embrace this approach indicates that there is still enthusiasm for a textbook on medical genetics; we will appreciate feedback from our readers as well.

The realities of editing an 11-volume set have become obvious to the three of us as editors. We are grateful to our authors, many of whom have contributed to multiple past volumes, including some who have updated their contributions from the first or second editions. We are also indebted to staff from Elsevier, particularly Peter Linsley and Pat Gonzalez, who have worked patiently with us in the conception and production of this large project. Finally, we thank our families, who have indulged our occasional disappearances into writing and editing. As always, we look forward to feedback from our readers, as this has played a critical role in shaping the evolution of *Principles and Practice of Medical Genetics and Genomics* in the face of the exponential changes that have occurred in the landscape of our discipline.
Preface to Clinical Principles and Applications

This volume of Principles and Practice of Medical Genetics and Genomics presents topics focused on fundamental principles that underlie clinical applications of genetics and genomics. Some of the authors (Robert J. Desnick, John M. Graham, Kenneth Lyons Jones, and Marilyn Jones) have composed and updated their chapters since the first or second editions of this treatise. Due to the recognition of the evolution of genomic, not just genetic, application, a number of new chapters have been added since the sixth edition. The knowledge and perspectives gained from the chapters in this volume provide the foundation for interpreting and applying the information contained in all subsequent volumes.

Reed E. Pyeritz, MD, PhD
1

A Clinical Approach to the Dysmorphic Child

Kenneth L. Jones¹,², and Marilyn C. Jones¹,²

¹Department of Pediatrics, University of California, San Diego, CA, United States
²Rady Children’s Hospital, San Diego, CA, United States

Abstract

This chapter outlines a clinical approach to the child with structural defects, defines many terms used in dysmorphology, and presents a parsimonious approach to genetic testing.

Keywords

Malformation; Deformation; Disruption; Dysplasia; Single primary defect; Sequence; Multiple malformation syndrome; Etiology; Pathogenesis; Prognosis; Recurrence risk; Chromosome; Comparative genomic hybridization; Whole exome sequencing

1.1. Introduction

The purpose of this chapter is to present a clinical approach to the child with structural defects. The approach is predicated on the concept that the nature of the structural defects presents clues to the time of onset, mechanism of injury, and probable etiology of the problem, all of which determine the direction of the evaluation. It presumes that the dysmorphic child represents an experiment in human development, which, if interpreted correctly, can provide
answers regarding the etiology of various structural defects, as well as permit insights into mechanisms of normal and abnormal morphogenesis. The method on which this approach is based has been most articulately set forth by Sir Arthur Conan Doyle’s fictional character Sherlock Holmes, who showed “how much an observant man might learn by accurate and systematic examination of all that came within his way” [1]. This chapter adapts this method to the evaluation of the child with structural defects. By sharpening the faculties of observation, the clinician can narrow systematically the diagnostic possibilities so that the laboratory and the literature can be consulted in a rational fashion to arrive at an accurate diagnosis. The precise cause of many malformations and malformation syndromes is not known. However, careful clinical evaluation in combination with an expanded range of cytogenetic, cytogenomic, and molecular testing has allowed the elucidation of the mechanism underlying a growing list of clinical disorders. The separation between genetic and environmental factors as well as cytogenetic (copy number) and single gene abnormalities is somewhat arbitrary. However, the approach is intended to be practical and to facilitate detection and prevention of human malformations. Gorlin’s Syndromes of the Head and Neck [2] and Smith’s Recognizable Patterns of Human Malformation [3] are particularly useful. In recent years, computerized databases available online and on CD-ROM have become useful adjuncts to diagnosis (London Dysmorphology Database [Face2Gene]; Possum Web [4]; Online Mendelian Inheritance in Man [5]; and Decipher [6]).

1.2. Prenatal Versus Postnatal Onset of Developmental Problems

A method of approach to children with structural defects is set forth diagrammatically in Fig. 1.1. Although the lists of exceptions is growing, a history and physical examination usually make it possible to determine if the structural abnormality is of prenatal or postnatal onset. In this chapter, “prenatal onset” designates structural abnormalities that are present at birth, and “postnatal onset”
designates structures that have previously developed and differentiated normally. Whereas the genetic alteration responsible for many of the disorders included under postnatal-onset structural defects is present at the time of conception, the structural manifestations of that genetic alteration do not become obvious until postnatal life. On the basis of this distinction, a more rational approach to the problem can be developed, as this determination narrows considerably the diagnostic probabilities and, it is hoped, permits a more judicious selection of adjunctive laboratory tests.

Generally speaking, prenatal-onset problems in development are a consequence of genetic or chromosomal (copy number) alterations that cause programming problems in the development and/or differentiation of structure or are the result of factors unique to the pregnancy itself, such as environmental agents, abnormalities of placentation, or mechanical constraint. Although always evident at birth, most prenatal-onset problems remain static or improve postnatally without evidence of neurologic deterioration. By contrast, postnatal-onset problems in development usually result in deterioration in structure or function that has previously been normal. Deterioration may reflect postnatal accumulation of a toxic metabolic product (as in phenylketonuria), progressive storage of a metabolite (as in Hurler syndrome), deteriorating energy production (as in mitochondrial myopathies), or ongoing infection (as in deafness from cytomegalovirus). Children with postnatal problems usually appear to have thrived in utero. The structural and functional consequences of the problem manifest after the newborn period.
Certain historical information can be particularly helpful in determining onset of the problem. Structural defects of prenatal onset are frequently associated with the following abnormalities noted by the mother during pregnancy and at the time of delivery, whereas, by contrast, with postnatal-onset structural defects, the pregnancy and delivery usually are normal.

Alterations of pregnancy associated with prenatal onset of developmental problems are as follows:

1. Alterations in gestational timing (prematurity or postmaturity). As discussed in several other chapters, the majority of conceptuses do not survive to be born at 40 weeks’ gestation. Much of this loss occurs in the very early part of pregnancy and is the result of gross chromosomal abnormalities and/or malformation. Numerous studies have documented an increased frequency of chromosomal and genetic abnormalities in losses from the second and third trimesters. Thus, premature delivery may reflect late fetal wastage rather than maternal disease. Postmaturity rarely occurs today because of improved fetal monitoring techniques. In years before the widespread use of ultrasound, anencephaly typically presented in pregnancies that continued well beyond